Heron Therapeutics Inc (NASDAQ:HRTX) has earned an average recommendation of “Buy” from the thirteen brokerages that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $31.13.

Several brokerages recently issued reports on HRTX. Oppenheimer reaffirmed a “buy” rating and set a $27.00 price objective on shares of Heron Therapeutics in a research note on Friday, November 10th. Northland Securities began coverage on shares of Heron Therapeutics in a research note on Wednesday, September 27th. They set an “outperform” rating and a $40.00 price objective for the company. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Sunday, November 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $31.00 price objective on shares of Heron Therapeutics in a research note on Thursday, November 2nd. Finally, Mizuho started coverage on shares of Heron Therapeutics in a research note on Tuesday, September 26th. They issued a “buy” rating and a $28.00 price target for the company.

Shares of Heron Therapeutics (NASDAQ:HRTX) traded up $0.30 during midday trading on Friday, reaching $23.20. 915,369 shares of the company traded hands, compared to its average volume of 1,120,538. Heron Therapeutics has a one year low of $12.25 and a one year high of $23.35. The stock has a market cap of $1,260.00, a PE ratio of -6.12 and a beta of 2.12. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The company had revenue of $8.57 million during the quarter, compared to analysts’ expectations of $8.12 million. research analysts anticipate that Heron Therapeutics will post -3.38 earnings per share for the current fiscal year.

In other news, VP Kimberly Manhard sold 7,584 shares of the stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total value of $151,680.00. Following the completion of the sale, the vice president now owns 7,584 shares of the company’s stock, valued at approximately $151,680. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 19.93% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC grew its stake in shares of Heron Therapeutics by 2.3% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock valued at $470,000 after buying an additional 771 shares during the period. Schwab Charles Investment Management Inc. grew its stake in shares of Heron Therapeutics by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock valued at $2,363,000 after buying an additional 1,026 shares during the period. HighTower Advisors LLC grew its stake in shares of Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after buying an additional 1,700 shares during the period. Tudor Investment Corp ET AL boosted its position in shares of Heron Therapeutics by 10.2% during the 2nd quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock worth $258,000 after purchasing an additional 1,724 shares during the period. Finally, Legal & General Group Plc boosted its position in shares of Heron Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 2,383 shares during the period. 98.21% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Heron Therapeutics Inc (HRTX) Given Average Recommendation of “Buy” by Brokerages” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://theolympiareport.com/2018/01/19/heron-therapeutics-inc-hrtx-given-average-recommendation-of-buy-by-brokerages.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.